We specialize in developing targeted therapies using advanced inhalation technologies delivering treatments directly to the site of disease with the aim of treating complex medical challenges. Our research focuses on respiratory diseases and transplant medicine, with a strong commitment to understanding disease mechanisms and creating innovative treatments. Through collaboration with leading researchers and institutions, we translate cutting-edge discoveries into transformative therapies
Improving outcomes for lung transplantation patients
KX01 is an inhaled anti-inflammatory and anti-fibrotic treatment in development for prevention and treatment of chronic lung allograft dysfunction (CLAD). Half of the lung transplanted patients develops CLAD within 5 years after the transplant. CLAD is a severe and life-threatening complication with a mortality rate of 50 % within 3 years of diagnosis.
Today there are no approved treatments for Lung transplantation patients.